Journals Progress in Cardiovascular Dis...

Progress in Cardiovascular Diseases
Vikash Jaiswal, Aanchal Sawhney, Chikodili Nebuwa, Vamsikalyan Borra, Novonil Deb, Anupam Halder, Kripa Rajak, Mayank Jha, Zarghoona Wajid, Rosy Thachil, Dhrubajyoti Bandyopadhyay, Jishanth Mattumpuram, Carl J Lavie
BACKGROUND: The Cardiovascular safety of testosterone replacement therapy (TRT) among men with hypogonadism is not well established to date. Hence, we sought to evaluate the cardiovascular disease (CVD) outcomes among patients receiving testosterone therapy by using all recently published randomized controlled trials. METHODS: We performed a systematic literature search on PubMed, EMBASE, and for relevant randomized controlled trials (RCTs) from inception until September 30th, 2023...
April 5, 2024: Progress in Cardiovascular Diseases
Chayakrit Krittanawong, Yusuf Kamran Qadeer, Hafeez Hassan Virk, Zhen Wang, Umair Khalid, Hani Jneid
No abstract text is available yet for this article.
March 26, 2024: Progress in Cardiovascular Diseases
Austin Tutor, Evan L O'Keefe, Carl J Lavie, Andrew Elagizi, Richard Milani, James O'Keefe
Even with substantial progress in primary and secondary prevention, cardiovascular disease (CVD) persists as a major cause of mortality and morbidity globally. Omega-3 polyunsaturated fatty acids (Ω-3 PUFAs) have gained considerable attention for their ability to improve CV health and prognosis. Metanalyses of randomized controlled trials have demonstrated Ω-3 PUFAs' positive impact on CVD outcomes for both primary and secondary prevention endpoints. Marine Ω-3 PUFAs also improve CVD risk factors including blood pressure, lipids, and inflammation; however, many physicians do not recommend Ω-3 PUFAs, largely due to inconsistent results in randomized trials...
March 26, 2024: Progress in Cardiovascular Diseases
Suvasini Lakshmanan, Janet Wei, Galen Cook-Wiens, Carl J Pepine, Eileen M Handberg, Leslee J Shaw, Matthew Budoff, C Noel Bairey Merz
OBJECTIVE: To compare baseline characteristics of participants in the Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR) trial by qualification by Coronary Computed Tomography Angiography (CCTA) or Invasive Coronary Angiography (ICA). METHODS: The WARRIOR trial (NCT03417388) is an ongoing multicenter, prospective, randomized, blinded outcome evaluation of intensive medical therapy vs. usual care in women with suspected Ischemia and No Obstructive Coronary Artery Disease (INOCA) identified by either CCTA or ICA on the outcome of major adverse cardiovascular events (MACE)...
March 26, 2024: Progress in Cardiovascular Diseases
Ross Arena, Deepika Laddu, Mark A Faghy
No abstract text is available yet for this article.
March 25, 2024: Progress in Cardiovascular Diseases
Giuseppe Lippi, Fabian Sanchis-Gomar, Carl J Lavie
No abstract text is available yet for this article.
March 20, 2024: Progress in Cardiovascular Diseases
Ksenija Zečević, Špela Volčanšek, Niki Katsiki, Manfredi Rizzo, Tanja Miličević Milardović, Anca Pantea Stoian, Maciej Banach, Emir Muzurović
Maturity-onset diabetes of the young (MODY) is a spectrum of clinically heterogenous forms of monogenic diabetes mellitus characterized by autosomal dominant inheritance, onset at a young age, and absence of pancreatic islets autoimmunity. This rare form of hyperglycemia, with clinical features overlapping with type 1 and type 2 diabetes mellitus, has 14 subtypes with differences in prevalence and complications occurrence which tailor therapeutic approach. MODY phenotypes differ based on the gene involved, gene penetrance and expressivity...
March 19, 2024: Progress in Cardiovascular Diseases
Mark A Faghy, Rae Duncan, Emily Hume, Lewis Gough, Clare Roscoe, Deepika Laddu, Ross Arena, Ruth E M Asthon, Caroline Dalton
The Post Covid-19 Condition (commonly known as Long Covid) has been defined by the World Health Organisation as occurring in individuals with a history of probable or confirmed SARS CoV 2 infection, usually within 3 months from the onset of acute Covid-19 infection with symptoms that last for at least two months which cannot be explained by an alternative diagnosis. Long Covid is associated with over two hundred recognised symptoms and affects tens of millions of people worldwide. Widely reported reductions in quality of life(QoL) and functional status are caused by extremely sensitive and cyclical symptom profiles that are augmented following exposure to physical, emotional, orthostatic, and cognitive stimuli...
March 8, 2024: Progress in Cardiovascular Diseases
Adham El Sherbini, Robert S Rosenson, Mahmoud Al Rifai, Hafeez Ul Hassan Virk, Zhen Wang, Salim Virani, Benjamin S Glicksberg, Carl J Lavie, Chayakrit Krittanawong
Artificial intelligence (AI) is a field of study that strives to replicate aspects of human intelligence into machines. Preventive cardiology, a subspeciality of cardiovascular (CV) medicine, aims to target and mitigate known risk factors for CV disease (CVD). AI's integration into preventive cardiology may introduce novel treatment interventions and AI-centered clinician assistive tools to reduce the risk of CVD. AI's role in nutrition, weight loss, physical activity, sleep hygiene, blood pressure, dyslipidemia, smoking, alcohol, recreational drugs, and mental health has been investigated...
March 7, 2024: Progress in Cardiovascular Diseases
Fernando de la Guía-Galipienso, Patricia Palau, Alejandro Berenguel-Senen, Carme Perez-Quilis, Jeffrey W Christle, Jonathan Myers, François Haddad, Aaron Baggish, Flavio D'Ascenzi, Carl J Lavie, Giuseppe Lippi, Fabian Sanchis-Gomar
Endurance and resistance physical activity have been shown to stimulate the production of immunoglobulins and boost the levels of anti-inflammatory cytokines, natural killer cells, and neutrophils in the bloodstream, thereby strengthening the ability of the innate immune system to protect against diseases and infections. Coronavirus disease 19 (COVID-19) greatly impacted people's cardiorespiratory fitness (CRF) and health worldwide. Cardiopulmonary exercise testing (CPET) remains valuable in assessing physical condition, predicting illness severity, and guiding interventions and treatments...
March 5, 2024: Progress in Cardiovascular Diseases
Nicolaas P Pronk, Bruce Y Lee
The purpose of this report is to provide a perspective on the use of qualitative systems mapping, provide examples of physical activity (PA) systems maps, discuss the role of PA systems mapping in the context of iterative learning to derive breakthrough interventions, and provide actionable recommendations for future work. Systems mapping methods and applications for PA are emerging in the scientific literature in the study of complex health issues and can be used as a prelude to mathematical/computational modeling where important factors and relationships can be elucidated, data needs can be prioritized and guided, interventions can be tested and (co)designed, and metrics and evaluations can be developed...
February 29, 2024: Progress in Cardiovascular Diseases
Laurie P Whitsel, Amy Bantham, Paul J Chase, Patrick Dunn, Lindsay Hovind, Brooke McSwain
Currently, assessing physical activity (PA) and cardiorespiratory fitness in healthcare settings and supporting patients on their journey toward active living is not a standard of practice in the US, although significant progress is underway. This paper summarizes the foundational as well as supporting public policies necessary to make PA assessment, prescription, and referral a standard of care in the US healthcare system to support active living for all. Measure standardization and healthcare integration will be supported by digital health and public private partnerships, as well as payer strategies and quality and performance incentives...
February 28, 2024: Progress in Cardiovascular Diseases
Srikanth Krishnan, Jairo Aldana-Bitar, Ilana Golub, Keishi Ichikawa, Ayesha Shabir, Marziyeh Bagheri, Hossein Hamidi, Travis Benzing, Sina Kianoush, Matthew J Budoff
The debate over the cardiovascular (CV) implications of testosterone therapy (TT) have resulted in diverging safety recommendations and clinical guidelines worldwide. This narrative review synthesizes and critically evaluates long-term studies examining the effects of TT within the context of aging, obesity, and endogenous sex hormones on CV disease (CVD) risk to support informed clinical decision-making. Observational studies have variably linked low endogenous testosterone with increased CVD risk, while randomized controlled trials (RCTs) demonstrate that TT yields cardiometabolic benefits without increasing short-term CV risk...
February 27, 2024: Progress in Cardiovascular Diseases
Jairo Aldana-Bitar, Ilana S Golub, Jeff Moore, Srikanth Krishnan, Dhiran Verghese, Venkat S Manubolu, Travis Benzing, Keshi Ichikawa, Sajad Hamal, Sina Kianoush, Lauren R Anderson, Noah R Ramirez, Jonathon A Leipsic, Ronald P Karlsberg, Matthew J Budoff
Colchicine is an anti-inflammatory medication, classically used to treat a wide spectrum of autoimmune diseases. More recently, colchicine has proven itself a key pharmacotherapy in cardiovascular disease (CVD) management, atherosclerotic plaque modification, and coronary artery disease (CAD) treatment. Colchicine acts on many anti-inflammatory pathways, which translates to cardiovascular event reduction, plaque transformation, and plaque reduction. With the FDA's 2023 approval of colchicine for reducing cardiovascular events, a novel clinical pathway opens...
February 27, 2024: Progress in Cardiovascular Diseases
Meghan M JaKa, Jeanette Y Ziegenfuss, Jennifer M Dinh, Laura J Jacobson, Thomas E Kottke, Susan M Knudson, Chad C Heim, Jason M Gallagher, Kevin D Campbell, Rachael L Rivard, Nicolaas P Pronk
BACKGROUND: Since the COVID-19 pandemic health systems have shifted necessarily from chronic to infectious disease treatment, but chronic disease remains critical. One large health system uniquely tracks member health behaviors. This analysis compares data from select months of an ongoing monthly cross-sectional survey before and during the pandemic. METHODS: Responses in April 2019 (pre-pandemic), April 2020 (early pandemic) or April 2021 (later pandemic) were included in the primary analysis (N = 252)...
February 27, 2024: Progress in Cardiovascular Diseases
David Martinez-Gomez, Fernando Rodriguez-Artalejo, Ding Ding, Ulf Ekelund, Veronica Cabanas-Sanchez
OBJECTIVE: To examine the trends in the association between meeting the physical activity (PA) guidelines and mortality in adults. METHODS: We included seventeen annual representative samples of US adults 1998-2014 (n = 482,756) and all-cause and cause-specific mortality ascertained through December 2019. Participants were grouped according to PA Guidelines: 150 or more min/week in aerobic PA and muscle-strengthening activities 2 or more times/week...
February 26, 2024: Progress in Cardiovascular Diseases
Matthew P Harber, Jonathan Myers, Amanda R Bonikowske, Adria Muntaner-Mas, Pablo Molina-Garcia, Ross Arena, Francisco B Ortega
Cardiorespiratory fitness (CRF) is a well-established biomarker that has applications to all adults across the health and disease spectrum. Despite the overwhelming evidence supporting the prognostic utility of CRF, it remains vastly underutilized. CRF is optimally measured via cardiopulmonary exercise testing which may not be feasible to implement on a large scale. Therefore, it is prudent to develop ways to accurately estimate CRF that can be applied in clinical and community settings. As such, several prediction equations incorporating non-exercise information that is readily available from routine clinical encounters have been developed that provide an adequate reflection of CRF that could be implemented to raise awareness of the importance of CRF...
February 26, 2024: Progress in Cardiovascular Diseases
Cemal Ozemek, Joel Hardwick, Amanda Bonikowske, Jeffrey Christle, Charles German, Satyajit Reddy, Ross Arena, Mark Faghy
Graded exercise testing is a widely accepted tool for revealing cardiac ischemia and/or arrhythmias in clinical settings. Cardiopulmonary exercise testing (CPET) measures expired gases during a graded exercise test making it a versatile tool that helps reveal underlying physiologic abnormalities that are in many cases only present with exertion. It also characterizes one's health status and clinical trajectory, informs the therapeutic plan, evaluates the efficacy of therapy, and provides submaximal and maximal information that can be used to tailor an exercise intervention...
February 26, 2024: Progress in Cardiovascular Diseases
Mark A Faghy, Caroline Dalton, Rae Duncan, Ross Arena, Ruth E M Ashton
Cardio-respiratory fitness (CRF) is well-established in the clinical domains as an integrative measure of the body's physiological capability and capacity to transport and utilise oxygen during controlled bouts of physical exertion. Long COVID is associated with >200 different symptoms and is estimated to affect ~150 million people worldwide. The most widely reported impact is reduced quality of life and functional status due to highly sensitive and cyclical symptoms that manifest and are augmented following exposure to physical, emotional, orthostatic, and cognitive stimuli, more commonly known as post-exertional symptom exacerbation (PESE) which prevents millions from engaging in routine daily activities...
February 26, 2024: Progress in Cardiovascular Diseases
Zach Cooper, Wendy Avila Rodriguez, Joel Hardwick, Ross Arena, Deepika R Laddu
Cardiorespiratory fitness (CRF), heavily influenced by physical activity (PA), represents a strong and independent risk factor for a wide range of health conditions, most notably, cardiovascular disease. Substantial disparities in CRF have been identified between white and non-white populations. These disparities may partly account for group differences in susceptibility to poor health outcomes, including non-communicable disease. Race and ethnic differences in CRF may partly be explained by social injustices rooted in persistent structural and systemic racism...
February 26, 2024: Progress in Cardiovascular Diseases
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.